ATE297910T1 - Retinoid x rezeptormodulatoren - Google Patents
Retinoid x rezeptormodulatorenInfo
- Publication number
- ATE297910T1 ATE297910T1 AT02728502T AT02728502T ATE297910T1 AT E297910 T1 ATE297910 T1 AT E297910T1 AT 02728502 T AT02728502 T AT 02728502T AT 02728502 T AT02728502 T AT 02728502T AT E297910 T1 ATE297910 T1 AT E297910T1
- Authority
- AT
- Austria
- Prior art keywords
- retinoid
- receptor modulators
- solvates
- hydrates
- directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27588501P | 2001-03-14 | 2001-03-14 | |
PCT/US2002/008292 WO2002071827A2 (en) | 2001-03-14 | 2002-03-14 | Retinoid x receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE297910T1 true ATE297910T1 (de) | 2005-07-15 |
Family
ID=23054229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02728502T ATE297910T1 (de) | 2001-03-14 | 2002-03-14 | Retinoid x rezeptormodulatoren |
Country Status (10)
Country | Link |
---|---|
US (2) | US7348359B2 (de) |
EP (1) | EP1373240B1 (de) |
JP (1) | JP2004532194A (de) |
AT (1) | ATE297910T1 (de) |
AU (1) | AU2002258550B2 (de) |
CA (1) | CA2438586A1 (de) |
DE (1) | DE60204674T2 (de) |
ES (1) | ES2244772T3 (de) |
MX (1) | MXPA03007779A (de) |
WO (1) | WO2002071827A2 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI279401B (en) | 1999-08-31 | 2007-04-21 | Incyte San Diego Inc | Heterocyclic derivatives for the treatment of diabetes and other diseases |
EA200300982A1 (ru) | 2001-03-07 | 2004-12-30 | Инсайт Сан Диего, Инк. | Гетероциклические производные для лечения рака и других пролиферативных заболеваний |
CA2473156A1 (en) | 2001-03-08 | 2002-09-19 | Incyte San Diego, Inc. | Rxr activating molecules |
US7173134B2 (en) | 2001-09-25 | 2007-02-06 | Smithkline Beecham Corporation | Selective RXR ligands |
AU2002352706A1 (en) | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
DE102004021637A1 (de) * | 2004-05-03 | 2005-12-01 | Merck Patent Gmbh | Dihydrobenzothiophene |
FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2890072A1 (fr) | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
US7855225B2 (en) | 2006-03-02 | 2010-12-21 | Astellas Pharma Inc. | 17βHSD type 5 inhibitor |
FR2933609B1 (fr) * | 2008-07-10 | 2010-08-27 | Fournier Lab Sa | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
MX2011005943A (es) | 2008-12-05 | 2011-06-27 | Abbott Lab | Derivados de tieno[3,2-c]piridina como inhibidores de cinasa para utilizarse en el tratamiento de cancer. |
WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
MX2012004990A (es) | 2009-10-30 | 2012-06-12 | Janssen Pharmaceutica Nv | Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10. |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EP2723744B1 (de) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-chinoxalin-derivate |
WO2013012909A1 (en) | 2011-07-20 | 2013-01-24 | Abbott Laboratories | Kinase inhibitor with improved aqueous solubility |
JP6426603B2 (ja) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ.ベー. | 神経障害または代謝障害の治療に使用するための、1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]−キノキサリン化合物などのPDE2阻害剤とPDE10阻害剤との組合せ |
EP2869822B1 (de) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Hemmer des phosphodiesterase-10-enzyms |
JP6723752B2 (ja) * | 2015-02-10 | 2020-07-15 | 公益財団法人相模中央化学研究所 | 二次電池用電解液 |
EP3365340B1 (de) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclische verbindungen als immunmodulatoren |
MX2018006207A (es) | 2015-11-19 | 2018-09-05 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
LT3394033T (lt) | 2015-12-22 | 2021-03-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
CN105693648A (zh) * | 2016-03-01 | 2016-06-22 | 浙江博仕达作物科技有限公司 | 一种氟苯噁唑类化合物及其用途 |
TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4137489A1 (de) | 2016-06-20 | 2023-02-22 | Incyte Corporation | Heterocyclische verbindungen als immunmodulatoren |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
MX2019007416A (es) | 2016-12-22 | 2019-12-11 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11795148B2 (en) | 2017-12-12 | 2023-10-24 | Queen's University At Kingston | Compounds and methods for inhibiting CYP26 enzymes |
CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
RS64188B1 (sr) | 2018-05-11 | 2023-06-30 | Incyte Corp | Tetrahidro-imidazo[4,5-c]piridin derivati kao pd-l1 imunomodulatori |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
KR20230117573A (ko) | 2020-11-06 | 2023-08-08 | 인사이트 코포레이션 | Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법 |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0678086T3 (da) * | 1993-01-11 | 2000-04-17 | Ligand Pharm Inc | Forbindelser med selektivitet over for retinoid-X-receptorer |
US5399586A (en) * | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
DK0775103T3 (da) * | 1994-08-10 | 1999-11-15 | Hoffmann La Roche | Retinsyre-X-receptorligander |
CA2383565A1 (en) | 1999-09-14 | 2001-03-22 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
-
2002
- 2002-03-14 AT AT02728502T patent/ATE297910T1/de not_active IP Right Cessation
- 2002-03-14 EP EP02728502A patent/EP1373240B1/de not_active Expired - Lifetime
- 2002-03-14 CA CA002438586A patent/CA2438586A1/en not_active Abandoned
- 2002-03-14 DE DE60204674T patent/DE60204674T2/de not_active Expired - Fee Related
- 2002-03-14 AU AU2002258550A patent/AU2002258550B2/en not_active Ceased
- 2002-03-14 US US10/471,330 patent/US7348359B2/en not_active Expired - Fee Related
- 2002-03-14 JP JP2002570800A patent/JP2004532194A/ja active Pending
- 2002-03-14 WO PCT/US2002/008292 patent/WO2002071827A2/en active IP Right Grant
- 2002-03-14 ES ES02728502T patent/ES2244772T3/es not_active Expired - Lifetime
- 2002-03-14 MX MXPA03007779A patent/MXPA03007779A/es active IP Right Grant
-
2007
- 2007-08-23 US US11/895,278 patent/US20080090860A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60204674T2 (de) | 2006-05-18 |
US7348359B2 (en) | 2008-03-25 |
JP2004532194A (ja) | 2004-10-21 |
CA2438586A1 (en) | 2002-09-19 |
US20080090860A1 (en) | 2008-04-17 |
EP1373240B1 (de) | 2005-06-15 |
EP1373240A2 (de) | 2004-01-02 |
US20040167160A1 (en) | 2004-08-26 |
MXPA03007779A (es) | 2004-11-12 |
ES2244772T3 (es) | 2005-12-16 |
DE60204674D1 (de) | 2005-07-21 |
WO2002071827A3 (en) | 2003-04-10 |
AU2002258550B2 (en) | 2006-04-27 |
WO2002071827A2 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60204674D1 (de) | Retinoid x rezeptormodulatoren | |
HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
ATE297203T1 (de) | Antithrombotische mitteln | |
ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
EA200700099A1 (ru) | Производные пиридина | |
EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
ATE272633T1 (de) | Aromatische amiden | |
EP1248612A4 (de) | Neue substanzen und verbindungen als protease-inhibitoren | |
MY153023A (en) | Tropane derivatives useful in therapy | |
DK1392714T3 (da) | Steroider som agonister for FXR | |
CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
ATE374765T1 (de) | Substituierte heterocyclische amide | |
ATE302775T1 (de) | Carbolinderivate | |
NO20032208D0 (no) | Benzodiazepinderivater som GABA A reseptormodulatorer | |
SE0302760D0 (sv) | New compounds | |
MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
RS51200B (sr) | (imidazol-1-il-metil)-piridazin kao blokator nmda receptora | |
BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
ATE346067T1 (de) | Carbolinderivate | |
ATE505462T1 (de) | Neue biologischaktive molekü le | |
ATE375985T1 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
ATE308540T1 (de) | Antithrombosemittel | |
DK1204658T3 (da) | Benzofurylpiperazin-serotoninagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |